Targets in the use of biologics for asthma
Journal of Precision Respiratory Medicine · 2019
DOI: 10.2500/jprm.2019.190005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Precision Respiratory Medicine, 2019. Verfasst von John Oppenheimer.
Abstract (Originalsprache)
Asthma is a heterogeneous illness. Despite a vast array of treatment options, a significant proportion of patients with asthma continues to lack control of their illness. We now have a new class of asthma therapy in our armamentarium: biologic agents. Presently, the current pricing for all of the biologic agents exceeds measures of cost-effectiveness. Optimal patient selection, through phenotypic indices, is the only likely way to allow these agents to be cost effective. This review examined the literature regarding biologic agents, which stressed attempts at optimizing choice.
Zitieren
APA
Oppenheimer, J. (2019). Targets in the use of biologics for asthma. Journal of Precision Respiratory Medicine. https://doi.org/10.2500/jprm.2019.190005
Vancouver
Oppenheimer J. Targets in the use of biologics for asthma. Journal of Precision Respiratory Medicine. 2019. doi:10.2500/jprm.2019.190005
BibTeX
@article{Oppenheimer2019,
author = {Oppenheimer, John},
title = {Targets in the use of biologics for asthma},
journal = {Journal of Precision Respiratory Medicine},
year = {2019},
doi = {10.2500/jprm.2019.190005}
}
EUVIMED